Hajimu Kurumatani
Overview
Explore the profile of Hajimu Kurumatani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirano A, Kadoya H, Takasu M, Iwakura T, Kajimoto E, Tatsugawa R, et al.
Microcirculation
. 2024 Sep;
31(8):e12889.
PMID: 39348278
Objective: Endothelial dysfunction plays an important role in the pathogenesis of chronic kidney disease. Prostacyclin (PGI), an endothelial cell-produced endogenous prostaglandin, plays a crucial role in maintaining endothelial function. However,...
2.
Nakajo I, Inoue H, Inaba M, Oikawa K, Katashima M, Sawamoto T, et al.
Clin Drug Investig
. 2021 Apr;
41(6):549-555.
PMID: 33913081
Background And Objectives: Beraprost sodium (BPS), an orally administrable prostaglandin I derivative, is used for the treatment of chronic arterial occlusion and pulmonary arterial hypertension and has potential efficacy in...
3.
Kurumatani H, Okada K, Origasa H, Fujita T, Isono M, Nakamoto H
Ther Apher Dial
. 2020 Dec;
25(5):551-564.
PMID: 33340238
We conducted a multicenter, randomized, double-blind, placebo-controlled, phase IIb/III study (CASSIOPEIR) using a renal composite endpoint (i.e., doubling of SCr or end-stage renal disease) in seven Asian countries/region. CASSIOPEIR compared...
4.
Nakamoto H, Yu X, Kim S, Origasa H, Zheng H, Chen J, et al.
Ther Apher Dial
. 2019 May;
24(1):42-55.
PMID: 31119846
TRK-100STP, a sustained-release preparation of the orally active prostacyclin analogue beraprost sodium, targets renal hypoxia. This study aimed to show the superiority of TRK-100STP over placebos in patients with chronic...
5.
Shimamura M, Miyakawa J, Doi M, Okada K, Kurumatani H, Mori Y, et al.
J Clin Pharmacol
. 2016 Sep;
57(4):524-535.
PMID: 27681484
The purpose of the present study was to evaluate the pharmacokinetics of beraprost sodium (BPS) and its active enantiomer, BPS-314d, in Japanese subjects with impaired kidney function. The plasma and...
6.
Koyama A, Fujita T, Gejyo F, Origasa H, Isono M, Kurumatani H, et al.
BMC Nephrol
. 2015 Oct;
16:165.
PMID: 26475266
Background: Evidence increasingly points to the importance of chronic hypoxia in the tubulointerstitium as a final common pathway to end-stage renal disease (ESRD). Beraprost sodium (BPS) is an orally active...
7.
Nakamoto H, Fujita T, Origasa H, Isono M, Kurumatani H, Okada K, et al.
BMC Nephrol
. 2014 Sep;
15:153.
PMID: 25233856
Background: Chronic kidney disease (CKD) is public health concern even in Asian countries. TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening...
8.
Goto Y, Yamaguchi S, Tamura M, Mochizuki H, Kurumatani H, Okano K, et al.
Prostaglandins Other Lipid Mediat
. 2014 Jul;
112:16-26.
PMID: 24992870
We have previously demonstrated that renoprotective effects of a prostacyclin analog, beraprost sodium, on the kidney of anti-glomerular basement membrane glomerulonephritis (GN) rats. The aim of this study is to...
9.
Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, et al.
Eur J Pharmacol
. 2013 Aug;
714(1-3):325-31.
PMID: 23911885
Beraprost sodium, a stable prostacyclin analog, was showed to improve survival rates in two different rat models, anti-glomerular basement membrane (GBM) glomerulonephritis (GN) and 5/6 nephrectomized (Nx) chronic kidney disease...
10.
Sato N, Kaneko M, Tamura M, Kurumatani H
Diabetes
. 2010 Jan;
59(4):1092-100.
PMID: 20068136
Objective: The prostacyclin analog, beraprost sodium (BPS), was examined for its potential to improve the symptoms of obesity-type diabetes (i.e., hyperglycemia, hyperinsulinemia, dyslipidemia, histopathologic changes, and diabetic complications). Research Design...